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Introduction: Negative attitude towards drug therapy can foster limited adherence to
treatment, which remains one of the biggest obstacles for implementing effective treatments,
especially long term.
Purposes: The purposes of the study were 1) to evaluate the attitude towards drug therapy
among a representative sample of patients treated in a community psychiatric service using
30-item Drug Attitude Inventory (DAI-30); 2) to evaluate the DAI-30 dimensions, applying
factorial analysis; and 3) to highlight the socio-demographic and clinical variables correlated
to DAI-30 score and factors.
Methods: The DAI was administered, over a 7-month period, to all patients treated in our
psychiatric outpatient services who agreed to participate in this study and provided their
informed consent. Data were statistically analyzed.
Results: With a response rate of 63.3%, 164 females and 136 males completed the DAI-30
with an average score of 14.24 (±10.46 SD), indicating moderately positive attitude towards
drug therapy. The analysis of DAI-30 internal consistency confirmed its reliability
(Cronbach’s alpha=0.84). Our factorial analysis highlighted three factors: Factor 1
(Cronbach’s alpha=0.81), composed of 7 items which indicate positive, trustful attitude;
Factor 2 (Cronbach’s alpha=0.78), composed of 5 items indicating negative attitude of
suspiciousness; and Factor 3 (Cronbach’s alpha=0.66), composed of 4 items suggesting
defensive and control attitude towards drug therapy.
Discussion: Among the selected variables, “monotherapy” and “total number of hospitali-
zations” were negatively correlated to the final score of DAI-30, whereas being “married”
was positively correlated to it, in a statistically significant way, using the multiple linear
regression model. These correlations suggest that positive attitude towards drug therapy
could be reinforced by the condition of being married and reduced by relapses with
hospitalization, as literature highlighted, and, paradoxically, by a monotherapy, which
could suggest a sort of psychological dependence on therapy and, indirectly, on psychiatric
service, potentially correlated to the long-term treatments of our patients.
Keywords: attitude towards drugs, psychiatric disorders, community mental health center,
therapy adherence
Introduction
The lack of adherence to a therapeutic regimen is a complex and multifactorial
phenomenon and has constituted a well-known challenge since the dawn of
medicine.1 The World Health Organization identified some factors of treatment
non-adherent behaviour: socio-economic and clinical characteristics of patients,
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type of therapy and treatment, quality of the relationship
between professional and patient, other psychosocial char-
acteristics of environment.1 Between one-third and one-
half of drugs prescribed for chronic or long-term condi-
tions are not taken by patients according to the indications
of the prescribers.2 Adherence is greater in patients who
have an acute illness than in those who suffer from
a chronic illness.3 Poor therapeutic adherence is
a complex problem, often persistent and resistant to “gen-
eric” approaches,4–6 which requires complex interventions
to improve the overall quality of care.5–7 Poor adherence
to treatment represents the main cause of suboptimal clin-
ical outcome in all diseases,8,9 resulting in inefficient
utilization of economic resources.
In psychiatric practice, the lack of adherence to treat-
ment appears to be correlated both to the patient’s attitude
towards therapy, such as distrust, ambivalence, rejection
for unpleasant undesirable effects, and to the state of ill-
ness that, if acute and severe, can favour the refusal of
drug intake. The patient who does not adhere to treatment
can induce in the therapist feelings of impotence and
frustration, which can favour excessive pharmacological
prescription, interpreted as an expression of the so-called
“counter-transference desperation”.10 In psychiatry, the
patient often presents, at the same time, “continuous”
symptoms and “discontinuous” relationship with
treatment.11 A historical review of adherence in psychia-
tric disorders compared with organic ones,12 showed lower
adherence rates in patients taking antipsychotic drugs
(58%), compared to those who took treatments for physi-
cal disorders (76%), although this result could have been
biased due to different methodologies for measuring the
therapeutic adherence.12 Recently, a systematic review of
39 studies reported an average rate of non-adherence in
schizophrenia patients of 41%, which would increase to
50% when the analysis is restricted to more methodologi-
cally rigorous studies.13 It has been observed that about
75% of patients with schizophrenia stopped taking the
drugs within 2 years following the first hospital
discharge.14 In 2002, Rossi et al15 identified three critical
factors for therapeutic adherence related to person (atti-
tudes, judgments, personality traits, personal beliefs),
treatment (side effects and tolerability, complexity of treat-
ment, doctor–patient relationship, efficacy of treatment,
attitudes of rejection of therapy) and pathology (lack of
insight, grandiosity, depressive symptoms, cognitive defi-
cits). The conceptualisation of medication adherence is
complex and, in accordance with some authors, illness
and treatment-related subjective attitudes may be more
relevant for collaboration in outpatient antipsychotic drug
treatment than side effects, cognitive functioning or any
socio-demographic variable.16 Although continued use of
anti-psychotic treatment after symptom remission is sus-
tained by most guidelines, poor therapeutic adherence
remains the major obstacle for the treatment of patients
with schizophrenia and other psychoses.17 A recent sys-
tematic review has estimated at 3% the one-year recur-
rence rate for patients who continued antipsychotics
whereas the risk of recurrence is increased to over 90%
among patients who had discontinued antipsychotic ther-
apy within 2 years.18 There is a general consensus on the
fact that lack of adherence represents the major criticality
in treatments, especially long-term ones, in the most
severely ill patients19 with further negative repercussions
on both the patient’s quality of life and Mental Health
Services.20 One of the most immediate consequences of
lack of adherence is a high rate of relapse, which can
favour the so-called “revolving door” phenomenon.21
Patients with relapses have a greater risk of self-injurious
behaviour, increased suicide and death rates, greater diffi-
culty in re-entering the workforce and risk of remaining
dependent on their families,22 with worsening of quality of
life and family and social relationships.23,24 In turn, as the
CUTLASS study showed, the best adherence derives from
a better quality of life.25 Although most studies are based
on populations affected by schizophrenic spectrum disor-
ders, similar difficulties in maintaining drug treatment for
a long period are present in patients affected by bipolar
disorders26,27 and other mood disorders.28 A more recent
systematic review, after having analysed 36 prospective
and observational articles, divided the non-adherence fac-
tors in severe psychiatric illnesses into “intentional and
unintentional”.29 Among intentional non-adherence, the
significant variables were the degree of illness insight,
the attitude towards drugs and the therapeutic alliance.
More detailed analyses that explored the relationship
between these variables suggested that the positive effect
of insight or disease awareness and therapeutic alliance on
adherence is indirect and likely mediated by positive atti-
tude and judgement towards drug therapy.30–32 Another
study highlighted a complex relationship between side
effects and adherence characterized by correlations of
opposite polarity that “compete” with each other; on the
one hand, the deterrent impact of unpleasant adverse
effects and on the other the patient’s willingness to tolerate
them in exchange for beneficial effects.33 Regarding the
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unintentional factors of non-adherence, the use or abuse of
substances represents the variable most consistently iden-
tified by literature reviews, regardless of the type and stage
of psychiatric pathology.24,34-37 Lack of family and/or
social support are other factors that could contribute to
unintentional non-adherence; on the other hand, the posi-
tive attitude of family members towards therapy and their
active involvement in the treatment of schizophrenia
patients are significantly associated with positive
adherence.30,38 Good social support, such as the presence
of valid family assistance, helps the patient in taking
therapy, reducing the negative effect of substance abuse
or other factors.39 A pilot study by Sapra et al40 high-
lighted that the group of patients with psychosis at onset
having a good therapeutic relationship with caregivers are
more adherent to therapy than the group of patients with
multi-episodic schizophrenia. A more recent study has
highlighted that treatment adherence among patients suf-
fered from psychiatric disorders cannot be significantly
influenced by socio-demographic or clinical factors only,
but rather by attitudes toward medications, perceptions of
personal necessity for medication and concerns about its
potential adverse effects.28 A recent study has confirmed
that patients’ attitudes towards their medication influence
drug adherence in severe psychiatric patients.41 As
recently reported by some authors, the therapeutic adher-
ence can be significantly associated with illness insight
and “perceived treatment-related trauma” related to pre-
vious treatment experiences.42 A recent review on this
topic has reported that only long-term or pragmatic inter-
ventions focused on medication adherence showed suc-
cessful outcomes.43
Drug Attitude Inventory
The Drug Attitude Inventory (DAI) is a self-completed
questionnaire composed of 30 items (True/False), DAI-
30, on the effects of treatment with psychotropic drugs,
helping to identify the target of the pharmacotherapy
management.44 In 2001, a validation study of the Italian
version of the DAI-30 highlighted that the Italian version
maintained the psychometric properties of the original
questionnaire.45 The initial exploratory factor analysis,
although carried out in a relatively small sample, high-
lighted the same factors evidenced by the DAI authors.45
The questionnaire was subsequently validated in
Korean46 and in Turkish;47 its reduced 10-item version
was used in an Egyptian study.48 In Tunisia, it was vali-
dated by the study of Nakhli et al,49 which examined
a sample of 204 outpatients with schizophrenia, reporting
7 factors responsible for 59.9% of the overall variance,
with a Cronbach’s alpha of 0.88. The DAI-30 was used in
numerous studies as a questionnaire for predicting adher-
ence in schizophrenia and major depression patients.
Townsend et al50 used DAI-30 in a sample of 122 adoles-
cent patients diagnosed with heterogeneous psychiatric
disorders, where the questionnaire was shown to be
a valid tool even changing the dichotomous answers
True or False to ones ranged between 1 and 5 in a Likert
scale. Balestrieri et al51 analyzed the attitude towards
therapy using the DAI-30 in a homogeneous for pathology
sample of 145 patients treated in monotherapy with five
different antipsychotics. Similarly, a cross-sectional
analysis52 using the reduced version DAI-10 in 291
patients with schizophrenia highlighted that only some
variables, such as family support, insight of illness, ther-
apeutic alliance and number of psychiatric hospitaliza-
tions, significantly influenced drug attitude. Recently, the
reduced version DAI-10 administered to 60 patients with
schizophrenia showed that the group with the greatest
therapeutic adherence was that in which individualized
interventions had been implemented to encourage
a positive drug attitude.53
Purposes of the Study
The main objective of the present study is to evaluate the
attitude towards drug therapy of patients treated in an
outpatient psychiatric service using the DAI-30.
The secondary objectives are to evaluate the DAI-30
dimensions, applying factorial analysis, and to highlight
the demographic and clinical variables correlated to
DAI-30.
Materials and Methods
The Sample
The sample is represented by the patients treated in
a Community Mental Health Center (CMHC) located in
a Northern Italian city, during the period of data collection
(from 8/9/2018 to 8/4/2019), according to our inclusion
and exclusion criteria.
Inclusion criteria:
● All patients pharmacologically treated in our CMHC
during the study period who agreed to participate in
the study.
Dovepress Di Lorenzo et al
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● All the above who provided, or whose legal guardian
provided, written informed consent to the study.
Exclusion criteria:
● Patients not pharmacologically treated in the CMHC.
● Patients on first consultation in the CMHC.
● Patients unable to provide valid consent.
In order to collect a sample numerically representative of
our population, we calculated a sample size of 330 indivi-
duals from the population of 2,320 patients treated in 2018
at our CMHC, with a margin of error of 5%, assuming
a level of bilateral significance (α) of 0.05 and confidence
interval of 95%.
Design of the Study
This is a cross-sectional observational pilot study, carried
out by administering the DAI-30, already translated and
validated in Italian.45 The test was administered to patients
during CMHC opening hours from Monday to Saturday.
Patients were enrolled by two researchers authorized by
the Ethics Committee, who did not treated the study
patients. If participants were unable to independently com-
plete the DAI-30, the questionnaire was administered by
the researcher. Subsequently, the same researcher com-
pleted the form with the socio-demographic and clinical
variables of participants.
DAI-30
The criterion for scoring the questionnaire described by its
authors44 includes a total of 30 questions, 15 positive (the
expected responses will be T), which assess adherence,
and 15 negative (whose expected answers will be F),
which evaluate non-adherence. The sum of the obtained
score is expressed in a whole number ranged between −30
and +30.44
The original version of DAI includes 30 items (DAI-
30), which are distributed over 7 factors, according to
the validation study of the authors who built the scale.44
Factor 1 contains items that express feelings of well-
being that the patient attributes to the effects of drugs.
Factor 2 represents the negative effects that the patient
attributes to drugs; the sum of the items of these two
factors identifies a construct called “subjective response
to treatment”. The remaining five factors constitute “atti-
tudes and opinions” that are considered important in
determining therapeutic adherence: Factor 3 can be
interpreted as the patient’s idea of health or illness (for
example, the pills are taken when one is sick and not
when one is well); Factors 4 and 5 include items that
express the patient’s attitude regarding the control of
therapy intake; Factor 6 consists of two items formulated
to indicate what the patient believes on drug efficacy to
prevent relapses; Factor 7 concerns potential toxic
effects. The sum of the items of these last five factors
identifies a construct called the “attitude towards ther-
apy”. As reported in the work of the authors of the
questionnaire, Hogan et al,44 the DAI-30 can therefore
be divided into two sub-scales, one of the 14 items and
the other of 11. The remaining 5 items are omitted from
the evaluation. The first sub-scale, which includes
Factors 1 and 2, evaluates the “subjective response to
treatment”; the second, which includes the remaining
five factors, assesses the “attitude towards therapy”.
Selected Variables
1. Socio-demographic variables: age, sex, nationality,
marital status, schooling, work, living environment.
2. Clinical variables: psychiatric diagnosis according
to ICD-9-CM (International classification of dis-
eases, 9th revision, Clinical modification),54 num-
ber of psychiatric hospitalizations, time since the
last admission, period of care at CMHC, prescribed
drugs, modality of drug administration, mono/poly-
therapy, organic comorbidity, treatment in other
community services.
For each patient, the aforementioned variables were retro-
spectively collected from patient medical records and from
informatics database at CMHC and, after the anonymiza-
tion of personal data, inserted in an Excel database.
Statistical Analysis
We applied descriptive statistical analysis of the variables:
mean and standard deviation (SD) for continuous variables;
percentages for categorical variables. After having applied
skewness and kurtosis test for normality, we analysed con-
tinuous variables normally distributed using t-test and applied
non-parametric method (Kruskal Wallis test) for analysing
continuous variables not normally distributed. We analysed
categorical variables using Pearson’s chi-square test.
Cronbach’s alpha coefficient was applied to highlight
the internal consistency of DAI-30 in Italian version.
An exploratory factor analysis (EFA) was applied to
DAI-30 score, to preliminarily investigate the factors
Di Lorenzo et al Dovepress
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underlying the scale. The conventional approach of prin-
cipal factor analysis was used, followed by orthogonal
(varimax) and oblique (promax) rotation.55,56 To verify
the appropriateness of the analysis performed with the
orthogonal rotation, the oblique rotation of the factors
was carried out, which made it possible to assess the
interdependence of the factors themselves. The factors
highlighted by the orthogonal rotation were selected on
the basis of a dual criterion: eigenvalue >1 for each factor
(Kaiser’s criterion),57 subsequently confirmed by the
scree-plot. The items with factor loadings >0.40 on
a given factor were therefore identified as “good indicators
of a factor”. The greater the factor loading, the more
relevant the variable related to the factor. The Kaiser-
Meyer-Olkin (KMO) test58 was used to verify the suitabil-
ity of the sample for application of the factor analysis and
Bartlett’s spherical test to verify the applicability of the
factor analysis in our sample.
For each factor the internal consistency was calculated
by means of Cronbach’s alpha coefficient.
The DAI-30 score and the score of the items under-
lying the factors were correlated with the selected vari-
ables through a multiple linear regression test, stepwise
model. We applied the backward stepwise selection, con-
sidering variables for removal from the model if their
p-value was ≥0.2 and would reconsider previously deleted
variables for re-entry if their p-value was <0.1.
A p < 0.05 and two-sided alpha level of 0.05 were used
as the probability statistic level of significance. The statis-
tical analysis was conducted through the STATA 12 soft-
ware program version (2011).
Ethical Considerations
The present research was conducted in accordance with the
principles of the Helsinki Declaration (World Medical
Association, 1964) and good clinical practice. The study
was approved by the Ethics Committee of the “Area Vasta
Emilia Nord” (Prot. no. AOU 0023224/18 of 19-9-2018) and
was authorized by the local Department of Mental Health
and Drug Abuse (Decision no. 1843 of 5–10-2018).
Informed written consent was obtained from each patient or
their legal guardian before his/her participation in this study.
Results
Our Sample
During the data collection period, 300 participants, 164
females and 136 males, among the 474 patients who were
asked to participate in the study, agreed to correctly complete
the DAI-30, after having provided their informed consent,
with an overall response rate of 63.3%. In Figure 1, the flow
diagram of participants screened is shown. The sample size is
numerically close to the appropriate size to represent the
population of 2,320 patients treated in our CMHC in 2018.
The Selected Variables
Regarding the socio-demographic variables (Table 1), our
participants were 48.54 years old (minimum 18, maximum
85), without a statistically significant difference between
the two genders (p=0.65, Skewness/Kurtosis tests; t=1.88,
p=0.061, t-test). The majority of them was Italian (87%),
38% were employed, most of them had attended a middle
(37%) or high school (37%), without a statistically signif-
icant difference between the two genders; regarding mar-
ital status, women were more frequently married than men
(Pearson chi2=17.66, p<0.001) and lived in the marital
family in higher percentage than men (Pearson
chi2=16.59, p=0.002).
We did not highlight any statistically significant differ-
ence between the two genders regarding the clinical vari-
ables shown in Table 2. The patients of our sample had
quite a long history of psychiatric illness, being in care at
our CMHC for more than 10 years in 40% of cases. Most
of our patients (73%) were treated only in our community
services. Among the psychiatric diagnoses, schizophrenic
disorders and other psychoses were prevalent (34%), fol-
lowed by bipolar disorders (22%), personality disorders
(17%), neurotic disorders (14%), adjustment reactions
(7%) and alcohol and/or drug-induced mental disorders
(1%). An organic comorbidity was present in 45% of our
sample. Without any statistically significant difference
between the two genders, the majority of our sample
(83%) had not been hospitalized in a psychiatric ward in
the previous year (p<0.001, Skewness/Kurtosis tests;
males vs females, p=0.699, Kruskal–Wallis test) and each
patient had an average 1.74 psychiatric hospitalizations
from the illness onset (p<0.001, Skewness/Kurtosis tests;
males vs females, p=0.299, Kruskal–Wallis test).
All patients in our sample were taking drug therapy at the
time of DAI-30 administration, according to the inclusion
criteria. Most patients took an oral therapy (88%), consisting
mainly of antipsychotics (66%), which, in the different for-
mulations (oral, depot) are the most represented drugs in our
sample, followed by benzodiazepines and antidepressants
(60%) (Table 3). Both antidepressants (Pearson chi2=21.61,
Dovepress Di Lorenzo et al
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p=0.004) and benzodiazepines (Pearson chi2=8.24, p<0.001)
were most often prescribed in females. Polytherapy was pre-
scribed to most of our patients (81%), more often prescribed
to women compared to men (Pearson chi2=8.12, p=0.004).
The Analysis of DAI-30
We obtained an average score of 14.24 (±10.46 SD), with
a range between −26 and +30.
In Figure 2, the sum of each item score across patients
is shown.
We reported the lowest scores in the items 11, 12, 21
and 24 (Figure 2).
The Cronbach’s alpha coefficient associated with the
totality of the 30 items was 0.84, indicating a good relia-
bility and internal consistency of the DAI-30 (item-test
correlation=0.14).
Our sample of 300 participants proved to be numeri-
cally sufficient for validation analysis, since 10 individuals
per item are recommended by most statisticians59 or in
accordance with the “Rule of 5” (rule of thumb), which
foresees a minimum of 5 individuals per item.60
Our EFA highlighted 3 factors with eigenvalue >1,
according to the Kaiser’s criterion,57 able to explain 79%
of the variance of our sample. This result was successively
confirmed by the scree-plot (Figure 3). On the orthogonal
rotation (varimax) (Table 4), all but 14 items of the DAI-
30 presented factor loadings >0.40, distributed in the first
three factors. As shown in Table 4, the three factors are
loaded by 16 items with uniqueness values ranging from
0.38 to 0.70. The first factor, which explains 46% of
variance, is loaded by the greatest number of items (7
items out of 30); the second factor, loaded by 5 items,
explains 20% of the variance; the third factor, explaining
13% of variance, is loaded by 4 items. The oblique rota-
tion substantially showed that Factors 1, 2 and 3 were
positively correlated among themselves and explained
35%, 26% and 25% of variance respectively, for a total
variance of 86% (promax matrix).
The three factors we highlighted at EFA indicated the
following domains: the first factor, loaded by 7 items,
a positive attitude of trust and hope; the second factor,
loaded by 5 items, a negative attitude of suspicion and
harm; the third factor, loaded by 4 items, a defensive and
rational attitude towards drug therapy (Figure 4). Factor 1
showed good (Cronbach’s alpha=0.81) and Factor 2
showed acceptable internal consistency (Cronbach's
alpha=0.78), whereas Factor 3 presented questionable
2,320 
individuals in care at CMHC
20
individuals provided 
their informed 
consent, did not  
correctely complete 
the scale and were 
excluded from the 
study
300 
individuals provided 
their informed 
consent, correctly 
completed the scale 
and were included in 
the study
154 
individuls refused to 
partecipate in the 
study, did not give 
their informed 
consent and were 
excluded from the 
study
474 
individuals were asked 
to particiate in the study
Figure 1 The flow diagram of participants screened.
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internal consistency (Cronbach’s alpha=0.66), just above
the minimum threshold of acceptability of item aggrega-
tion (0.6), indicating a minor homogeneity of item
dimensions.
Further confirmation of the numerical adequacy of our
sample for EFAwas subsequently obtained by applying the
Table 1 Socio-Demographic Variables of Our Sample
Variables Sample
Male
N=136
(45%)
Female
N=164
(55%)
Total
N=300
(100%)
Age, mean±standard deviation
Years 46.83
±14.26
49.96
±14.38
48.5
±14.39
Nationality, n (%)
Italian 120 (88%) 142 (86%) 262 (87%)
European (no-Italian) 0 (0%) 6 (4%) 6 (2%)
Extra-European 16 (12%) 16 (10%) 32 (11%)
Marital status, n (%)
Single 77 (58%) 55 (34%) 132 (44%)
Married 44 (32%) 70 (43%) 114 (38%)
Divorced or widowed 14 (10%) 37 (23%) 51 (18%)
Schooling, n (%)
Elementary school 14 (10%) 17 (10%) 31 (10%)
Middle school 51 (37.5%) 59 (36%) 110 (37%)
High school 51 (37.5%) 59 (36%) 110 (37%)
University degree 11 (8%) 21 (13%) 32 (10%)
Unknown 9 (7%) 8 (5%) 17 (6%)
Work, n (%)
Employed 51 (38%) 62 (38%) 113 (38%)
Unemployed 44 (32%) 50 (30%) 94 (31%)
Retired for disabilty 20 (15%) 20 (12%) 40 (13%)
Retired for age 11 (8%) 20 (12%) 31 (11%)
Student 7 (5%) 8 (5%) 15 (5%)
Unknown 3 (2%) 4 (3%) 7 (2%)
Living environment, n (%)
Alone 30 (22%) 31 (19%) 61 (20%)
Parental family 44 (32%) 32 (20%) 76 (26%)
Marital family 44 (32%) 88 (53%) 132 (44%)
Protected facility 13 (10%) 8 (5%) 21 (7%)
Unknown 5 (4%) 5 (3%) 10 (3%)
Table 2 Clinical Variables of Our Sample
Variables Sample
Male
N=136
(45%)
Female
N=164
(55%)
Total
N=300
(100%)
Treatment in other community services, n (%)
No treatment in other
community services
100 (74%) 118 (71%) 218 (73%)
Substance Abuse Service 4 (3%) 2 (2%) 6 (2%)
Social Service 19 (14%) 25 (15%) 44 (15%)
Clinical Psychology
Service
10 (7%) 18 (11%) 28 (9%)
Others or more than
one service
3 (2%) 1 (1%) 4 (1%)
Psychiatric diagnoses (ICD-9-CM), n (%)
Schizophrenia and other
psychosis
59 (43%) 43 (26%) 102 (34%)
Bipolar disorders 23 (17%) 43 (26%) 66 (22%)
Neurotic disorders
(Dysthymia and anxiety
disorders)
15 (11%) 27 (16%) 42 (14%)
Personality disorders 20 (15%) 31 (19%) 51 (17%)
Alcohol and/or drug
induced mental
disorders
2 (1%) 1 (1%) 3 (1%)
Adjustment reactions 11 (8%) 11 (7%) 22 (7%)
Others 6 (5%) 8 (5%) 14 (5%)
Organic comorbidity, n (%)
Absent 79 (58%) 84 (51%) 163 (54%)
Present 56 (41%) 79 (48%) 135 (45%)
Not ascertainable 1 (1%) 1 (1%) 2 (1%)
Period of treatment in CMHC, n (%)
< 1 year 25 (18%) 27 (16%) 52 (18%)
1-10 years 55 (40%) 60 (37%) 115 (38%)
>10 years 50 (37%) 71 (43%) 121 (40%)
Not ascertainable 6 (5%) 6 (4%) 12 (4%)
Psychiatric hospitalizations from illness onset, mean
±standard deviation
Number 1.49±3.83 1.95±4.43 1.74±4.17
Psychiatric hospitalizations in the previous year, n (%)
1 or more than one 19 (14%) 27 (16%) 46 (15%)
None 114 (84%) 134 (82%) 248 (83%)
Not ascertainable 3 (2%) 3 (2%) 6 (2%)
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KMO test,58 which returned a value of 0.82, suggestive of
a “meritorious” sample (interval between 0.80 and 0.89).
The distribution of the sample according to Bartlett’s
spherical test was normal and suitable for the application
of the EFA (p<0.001).
The Variables Related to DAI-30 Score
We did not highlight any statistically significant difference
in the DAI-30 score among patients suffering from
a schizophrenic spectrum disorder and all other diagnoses
(p<0.001, Skewness/Kurtosis tests; p=0.23, Kruskal–
Wallis test) as well as between the two genders (p=0.65,
Skewness/Kurtosis tests; p=0.09, t-test).
As shown in Table 5, only three variables are statisti-
cally significantly correlated with the final score of the
DAI-30 using multiple linear regression (stepwise model):
● “married” marital status compared to “single”, in posi-
tive correlation (being married increases the DAI-30
score),
● number of psychiatric hospitalizations from the ill-
ness onset, in negative correlation (a lower total
number of admissions is associated with higher
scores of the DAI-30),
● monotherapy compared to polytherapy, in negative
correlation (monotherapy correlates to potentially
worsening perception of drug therapy).
In our stepwise model of multiple linear regression, as
seen in Table 5, the variables negatively correlated in
a statistically significant way to the three factors of the
DAI-30, are the following:
● number of psychiatric hospitalizations from illness
onset and the absence of antipsychotic therapy, with
Factor 1;
● work activity, represented by the status of “student”
and “retired for age”, with Factor 2;
● the absence of treatment in other community ser-
vices, with Factor 3.
Discussion
This cross-sectional observational 7-month study evalu-
ated the attitude towards drug therapy of people treated
at an outpatient psychiatric service using the DAI-30.
The participation of subjects was satisfactory: the aver-
age response rate was moderately high, accounting for
63.3% of respondents. The DAI-30 was easy to read and
administer, since only some items were difficult to inter-
pret. In particular, an item on which most respondents
asked for clarification was no. 24, which in fact obtained
the lowest score. All information and clarifications
requested were promptly given. The DAI-30 was adminis-
tered by a researcher other than each patient’s therapist in
order to eliminate, as far as possible, a compilation bias.
Our sample is equally distributed between the genders,
which show statistically significant differences only in
a few socio-demographic and clinical characteristics:
women were married and lived in the marital family
more often than men, who more frequently remained in
their parental family; women were treated with polythera-
pies and with antidepressants and benzodiazepines more
frequently than men. Both these observations overlap
those reported in the epidemiological literature.22,61,62
Most respondents were affected by schizophrenic and
psychotic spectrum disorders (34%), had suffered from
mental disorders for a long time (40% of our respondents
Table 3 Pharmacological Variables of Our Sample
Variables Sample
Male
N=136
(45%)
Female
N=164
(55%)
Total
N=300
(100%)
Drugs, n (%)
Oral and/or long-
acting antipsychotic
Present 100 (74%) 99 (60%) 199 (66%)
Absent 36 (26%) 65 (40%) 101 (34%)
Mood stabilizer Present 22 (16%) 34 (21%) 56 (19%)
Absent 114 (84%) 130 (79%) 244 (81%)
Benzodiazepine Present 69 (51%) 110 (67%) 179 (60%)
Absent 67 (49%) 54 (33%) 121 (40%)
Antidepressant Present 61 (45%) 117 (71%) 178 (60%)
Absent 75 (55%) 47 (29%) 122 (40%)
Other drugs Present 11 (8%) 27 (16%) 38 (13%)
Absent 125 (92%) 137 (84%) 262 (87%)
Modality of therapy administration, n (%)
Oral 116 (85%) 148 (90%) 264 (88%)
Long-acting 5 (4%) 1 (1%) 6 (2%)
Other or more than one modality 15 (11%) 15 (9%) 30 (10%)
Mono- or polytherapy, n (%)
Monotherapy 36 (26%) 22 (13%) 58 (19%)
Polytherapy 100 (74%) 142 (87%) 242 (81%)
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had been treated for more than 10 years), were clinically
improved at the moment of the DAI-30 administration
(83% of cases had not reported any hospitalization in the
previous year). 81% of our participants were treated with
a polytherapy and 88% with oral therapy, composed of
antipsychotics in 66% of cases.
0
50
100
150
200
250
300
350
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30
DAI-30 item
DAI-30
item
score
Figure 2 The sum of each DAI-30 item score across patients.
Figure 3 Scree-plot of DAI-30 factorial analysis.
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Our study, similar to other studies,50,63 evaluated drug
attitude using the DAI-30 in a large sample with hetero-
geneous diagnoses and care needs, which is representative
of the population treated in an Italian outpatient psychia-
tric service as highlighted by their socio-demographic and
clinical characteristics.64 Analysis of the reliability and
internal consistency of the DAI-30 questionnaire con-
firmed that it is a reliable tool (Cronbach’s coefficient
associated with the totality of the 30 items is equal to
0.84), as highlighted by other studies.44,45
In accordance with our factorial analysis, the DAI-30
is composed of three factors, supported by 16 items with
>0.40 factor loadings, which, albeit fewer, overlap the
psychological dimensions of those identified in the first
validation (7 factors).44 In particular, the first factor we
identified is loaded by the same items which loaded the
Factor 1 identified by Hogan et al,44 defined by the DAI-
30 authors “Subjective positive experience”; the second
factor is loaded by the same 5 items loading the Factor 2
identified by Hogan et al,44 who named it “Subjective
negative experience”; our two factors explain the major-
ity of variance (66%) as did the first two factors identified
by the DAI-30 authors (75%). Our third factor is loaded
by 4 items that indicate a defensive and control attitude
about drug therapy; two of these 4 items (items no. 1 and
13) are the same ones that loaded the third factor identi-
fied by Hogan et al,44 who defined it “Health/illness”,
suggesting the “patients’ models of health”. Our EFA
results overlap the Italian validation study,45 although,
among the 7 Factors highlighted by this study, only the
first two were loaded by most items and explained the
majority of the variance. These results confirm DAI-30
validity over time in showing the patients’ attitudes and
experiences regarding drug therapy, which is apparently
unchanged after 37 years from the inventory construc-
tion. Moreover, since we obtained the same results as the
DAI-30 authors, who differently from us applied the
inventory in a sample of patients affected by schizophre-
nia, we can infer that the attitude towards drug therapy
can be similar in different psychiatric disorders, repre-
senting a universal perception and experience of drug
therapy.
Table 4 Factor Loadings (>0.40) and Uniqueness of the DAI-30
Items
DAI-30
Items
Factor 1
(Factor
Loading)
Factor 2
(Factor
Loading)
Factor 3
(Factor
Loading)
Uniqueness
Item 1 0.60 0.55
Item 3 0.50 0.53
Item 4 0.57 0.60
Item 6 0.65 0.48
Item 9 0.45 0.60
Item 11 0.41 0.65
Item 12 0.64 0.52
Item 13 0.46 0.70
Item 15 0.70 0.42
Item 16 0.63 0.50
Item 18 0.70 0.43
Item 21 0.59 0.50
Item 22 0.58 0.58
Item 25 0.58 0.60
Item 26 0.74 0.38
Item 29 0.50 0.62
Factor 1
Cronbach’s alpha=0.81
Positive attitude of trust 
and hope towards drug 
therapy
Factor 3
Cronbach’s alfa=0.66
Defensive and control 
attitude towards drug 
therapy
Item 1
Item 4
Item 13
Item 22
Factor 2
Cronbach’s alpha=0.78
Negative attitude of 
suspicion and harm 
towards drug therapy
Item 11
Item 12
Item 16
Item 9
Item 15
Item 18
Item 21
Item 26
Item 29
Item 6
Item 3
Item 25
Figure 4 The three factors of DAI-30.
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The overall score obtained (14.24±10.46) in our sam-
ple indicates a moderately positive attitude towards drug
therapy. It suggests an attitude of trust in drug prescription
and, indirectly, in therapeutic relationship with therapists
of CMHC. This result is consistent with the literature,
which reports higher scores in stabilized outpatient and
in long-term care patients, characteristics presented by our
participants51,63 and lower scores in hospitalized and/or
acute illness patients.14,65 We did not find any statistically
significant difference in the DAI-30 score between patients
suffering from schizophrenic spectrum disorders and those
suffering from all other diagnoses. This result suggests
that the attitude evaluated through the DAI-30 is not
specific to the individuals affected by schizophrenic spec-
trum disorders but it is similarly present in patients suffer-
ing from other subacute psychiatric disorders treated in an
outpatient service.
In our multiple linear regression, two variables, "number
of psychiatric hospitalizations from the illness onset" and
"monotherapy", were negatively statistically significantly
correlated with the DAI-30 score, whereas the marital status
“married” was positively statistically significantly correlated
with the DAI-30 score. Each of the three factors we identified
was significantly and negatively related to different variables,
suggesting that “previous psychiatric hospitalizations” and
“no antipsychotic drug therapy” could be associated with
reduced positive attitude (Factor 1); whereas being “retired
for age” and being a “student” could be associated with
reduced negative attitude (Factor 2) and no treatment in
other community service with reduced defensive and control
attitude towards drugs (Factor 3). These results suggest the
specificity of the dimensions represented by the three factors
that are differently conditioned: the positive attitude
(Factor 1) by clinical variables; the negative attitude
Table 5 Variables Statistically Significantly Related to the DAI-30 Total and Factor Scores (Stepwise Multiple Linear
Regression Model)
Variable Coefficient Standard
Error
Probability 95% Confidence
Interval
The DAI-30 total score
Number of psychiatric hospitalizations from
illness onset
−0.32 0.15 p=0.033 −0.62; −0.02
Mono/Polytherapy
(“Polytherapy”)*
“Monotherapy”
−4.24 1.54 p=0.007 −7.29; −1.19
Marital status
(“single”)*
“married”
2.87 1.34 p=0.034 0.22; 5.53
Factor 1 score
Number of psychiatric hospitalizations from
illness onset
−1.25 0.47 p=0.008 −2.17; 0.33
Therapy with antipsychotic drugs
(“present”)*
“absent”
−2.24 0.61 p=0.000 −3.44; −1.03
Factor 2 score
Work
(“employed”)*
Retired for age
−1.23 0.60 p=0.042 −2.42; −0.046
Student −2.16 0.81 p=0.009 −3.77; −0.55
Factor 3 score
Treatment in other community services (“present”)*
“absent”
−0.73 0.33 p=0.027 −1.38; −0.08
Notes: *Reference variable
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(Factor 2) by socio-demographic ones; the defensive and
control attitude (Factor 3) by organizational ones.
These results are partially in line with the literature.
Being married or having a family is a well-known protec-
tive factor for the onset and prognosis of various psychia-
tric disorders either among schizophrenia spectrum30,38 or
mood disorders.66,67 Family support has been identified as
a protective factor for therapeutic adherence in another
study that used the DAI-30.52 The number of previous
psychiatric hospitalizations has been identified by most
studies as a factor that does not favour a positive attitude
towards drug therapy.20,21,26,27,50,68 This correlation indir-
ectly indicates the key role of therapeutic adherence in
avoiding repeated hospitalizations with the risk of aggra-
vating the illness course and increasing health care costs.
The positive correlation between polypharmacy and
DAI-30 score appears, at first glance, paradoxical and in
contrast with what emerged in the literature: the taking of
a polytherapy is accompanied by less manageability and
greater side effect, is often associated with reduced therapeu-
tic adherence and not recommended by the main interna-
tional guidelines.69–71 The possible efficacy of
a polypharmacy regime compared to monotherapy in parti-
cular clinical conditions is still a controversial topic in the
literature.72 Although international guidelines recommend
the prescription of antipsychotics in polypharmacy only as
at last step,73 in case of resistance and in particularly severe
forms, this practice is very common, particularly in outpati-
ent and long-term settings. The positive attitude towards
polytherapeutic regimes shown by our sample can be inter-
preted in light of the complexity and ambivalence feeling
which often characterizes the therapeutic relationship
between the patient and the therapists at CMHC. We can
hypothesize that patients treated long term in an outpatient
setting and in good clinical compensation (as evidenced by
the low rate of hospitalizations in the previous year), had
developed over time a good acceptability of pharmacological
therapy. Moreover, they appeared to show such extreme trust
in its efficacy as to overcome the negative counterpart repre-
sented by side effects and stigma potentially related to drug
therapy. A similar result was recently highlighted by Rej
et al63 the Dutch team, using DAI-30 in a cross-sectional
study, which showed that 78 patients with bipolar disorder
over the age of 60 who were treated with lithium had a more
favourable attitude towards drug therapy compared to others
not treated with lithium. This result was explained by the
authors with the greatest benefit obtained by the positive
action of lithium compared to its adverse effects. We
hypothesize that in our sample, drug therapy assumed such
positive and gratifying, and perhaps magically symbolic
values, as to overcome the difficulty of taking complex
polytherapy. On the other hand, our results suggest the pos-
sibility that a long-term therapeutic relationship, as in our
patients, can induce an attitude of relational dependence on
the therapist and, indirectly, on drug prescription and admin-
istration, and, symbolically, on the whole CMHC. Drugs
could represent a symbolic representation of a significant
figure such as the physician, if not even a surrogate of the
therapists during their absence in a sort of transference
phenomenon.74 Our results show that the perception of
drug therapy can represent what the patient thinks of disease,
the patient’s expectations and hopes, but, at the same time, it
expresses how much the therapist is able to accept patient
needs in an empathic way. Therefore, drug therapy can
represent an ambivalent object, invested by both the patient
and the physician with expectations and hope for future
improvement. Both drug prescription and administration
can assume opposite clinical meanings ranged between the
empathic sharing of the patient’s needs and the therapeutic
distancing from them, but, in any case, they are aimed at
counteracting the disease.74 Drug therapy prescription can
represent the climate and the organisation of therapeutic
settings, able to modify not only the patient’s condition but
also the setting itself. The complex psycho-pharmacological
therapeutic relationship does not only modify the clinical
effect of the drug, but can strongly condition the patient’s
ability to adhere to a treatment plan, in which drug therapy is
present as a central and indispensable part.
This leads us to highlight the importance of therapeutic
alliance between the patient and the therapist and the need
for constant attention to the patient’s internal experience
with drug therapies. DAI-30 can be a good predictor of
adherence, since it explores the treatment experiences and
healing expectations of patients and indirectly puts in evi-
dence their insight and awareness of illness. All these factors
together can strongly condition therapeutic adherence, as
reported by other studies.43 In accordance with other
authors, who proposed a patient-centered model of medica-
tion adherence, we report that “first step in finding solutions
for nonadherence is understanding patient motives for taking
or not taking prescribed medications”. 75
In light of our results, we remind that the patient experience
with drug therapy should be periodically but regularly
reviewed not only to avoid non-adherence behaviour, but
also to reduce the psychological dependence on drug therapy
and psychiatric service, which, although initially necessary in
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many cases in order to implement rehabilitative and psy-
chotherapeutic programs,76 can reinforce regressive
tendencies.
Limitations and Advantages of the
Study
Our study has some limitations. First, the cross-sectional
observational design of this study did not allow us to infer
causality among the variables observed. In particular, the
heterogeneity of psychiatric clinical disorders in our sam-
ple, which implies difference in treatment complexity and
therapeutic adherence, makes our results not exhaustively
interpretable. Furthermore, the DAI-30 score was not com-
pared with symptom severity or outcome scales or other
factors such as therapy interruption or psychiatric hospita-
lizations, which could have indicated in detail the correla-
tion between disease severity and therapeutic adherence.
Other studies focused on correlation between clinical fac-
tor and DAI score can deepen its predictability in thera-
peutic adherence and, indirectly, clinical outcome.
On the other hand, the strengths already mentioned are
represented by the sample size and the inclusion in the
same sample of patients with different psychiatric diag-
noses, representative of the patients treated in our commu-
nity mental health service.
Conclusions
This study confirms that the DAI-30 is a reliable tool, easy
to administer and to understand, which analyses three
different dimensions of attitude towards drug therapy:
trust and hope, suspicion and fear of harm, defence and
control, in accordance with our factorial analysis.
We highlighted a good emotional and therapeutic
atmosphere in our CMHC, suggested by the positive
score of the DAI-30 and the high rate of participation in
the study, both potential indicators of therapeutic adher-
ence. The correlations between the DAI-30 scores and the
selected socio-demographic and clinical variables indicate
that the positive attitude towards drug therapy can be
reinforced by family support and reduced by relapses
with hospitalization, as literature has highlighted.
Paradoxically, in our sample, polytherapy favoured
a positive attitude towards drugs. This last result suggests
a sort of psychological dependence on drug therapy and,
indirectly, on psychiatric service, that can be explained by
the long-term treatments of our patients.
Our results lead us to reflect on the risks of dependence
on drugs, especially in long-term treatments in a community
service setting. Therapists must be aware of this risk and
constantly monitor drug prescription within the therapeutic
relationship. The meaning that drug therapy assumes for the
patient should be correctly and periodically re-evaluated by
all members of the multidisciplinary team of a community
psychiatric service. In particular, the attitude towards drugs
can be an important indicator not only of the patient’s
expectations and illness awareness, but also of the thera-
pists’ ability to create a non-stigmatizing therapeutic rela-
tionship aimed at the patient’s autonomy and responsibility.
Future longitudinal studies are necessary to deepen the
understanding of such a complex and multifactorial phe-
nomenon as the attitude towards pharmacological therapy
in order to implement more appropriate strategies to pre-
vent the patients’ abandonment of treatments and, at the
same time, their dependence on therapy and psychiatric
service.
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